Executive Search for Specialty Pharma Launch Teams

Having placed leaders into roles like this repeatedly, we wrote this to give a practitioner’s view rather than generic advice. Building a specialty pharma launch team is a timing problem as much as a talent problem, because you must hire ahead of approval into roles that cannot yet be fully defined, while the approval date itself may move. Hire too early and you burn capital on leaders with insufficient work; hire too late and the launch is compromised, and the window between those errors is narrower than most companies expect.

The Timing Problem

Launch leadership must be in place months before approval to build the commercial infrastructure, secure access, prepare the field organisation, and design patient support, but the approval itself is uncertain in both outcome and timing. This creates a genuine dilemma with no clean answer. The practical approach is to sequence hires so that the roles with the longest lead times, market access, patient services design, key commercial leadership, come first, while roles that can be built quickly come later, and to be explicit with candidates about the uncertainty rather than presenting the timeline as settled.

Specialty Launches Need Different Commercial Profiles

Specialty and rare disease launches do not require large field forces; they require small, deeply knowledgeable teams who can engage credibly with specialist physicians, support complex reimbursement case by case, and manage patient identification. A commercial leader whose experience is building large primary care organisations may be genuinely accomplished and still wrong for this. Prioritise candidates who have launched specialty products into concentrated prescriber bases over those with broader but less relevant commercial scale.

Market Access Is Usually the Constraint

For specialty products, particularly high-cost ones, access determines whether the launch succeeds, and access capability takes longest to build because it depends on evidence, payer relationships, and preparation that cannot be compressed. In practice this often makes market access the first commercial hire rather than a later one, and companies that sequence it late frequently find their launch constrained by coverage problems that earlier work would have addressed. Treat access capability as a lead-time item comparable to manufacturing readiness.

Being Honest With Candidates

Executives joining pre-approval are taking real risk, and the companies that recruit well for launch teams are candid about it: what the regulatory position actually is, what the timeline assumes, what happens if approval is delayed or refused, and how the role and compensation are structured accordingly. Candidates who accept on an optimistic picture and then face a delay or a complete response letter leave, which is worse than not having hired them. Straightforward disclosure attracts candidates who can genuinely handle the uncertainty, which is who you want.

What This Looks Like in Practice

A specialty pharma company sequences launch hiring by lead time, placing market access and patient services capability early, recruits commercial leaders with concentrated-prescriber specialty launch experience rather than large-scale primary care backgrounds, and is candid with candidates about regulatory position, timeline assumptions, and contingencies if approval slips.

The Mistake Employers Keep Making

The most common mistake is sequencing market access late, treating it as a launch-year activity while hiring field leadership first. Because access depends on evidence and payer preparation that cannot be compressed, this frequently produces a launch where the product is approved but coverage is not in place, and the commercial team has nothing to sell into. The company sequences by visibility rather than by lead time.

Sequencing a Specialty Launch Team

The Bottom Line

Specialty launch hiring is a sequencing problem under regulatory uncertainty, so place the longest lead-time capabilities, particularly market access, earliest, recruit commercial leaders with genuine specialty launch experience, and be candid with candidates about the risk they are accepting. The employers who hire well here are the ones who respect what makes the role specific, and search accordingly.

Related Reading

For more, see What Makes a Great VP of Market Access in Pharma, Recruiting for Rare Disease and Orphan Drug Companies, Building an Executive Team for a Pre-Commercial Biotech.

Tanya Gallardo

Managing Director, Executive Search & AI Talent Strategy

Tanya Gallardo is the Managing Director of Executive Search & AI Talent Strategy at JRG Partners, leading C-suite and Board engagements across key growth sectors including Technology, Financial Services, and Manufacturing.

With over 18 years of experience specializing in disruptive technology leadership, Tanya is recognized as a leading authority on talent architecture for future-focused executive roles, such as the Chief AI Officer (CAIO) and Chief Digital Officer (CDO). Her expertise lies in accurately assessing the cultural fit and technical depth required to ensure a high return on investment (ROI) for critical leadership appointments.

Prior to her role at JRG Partners, Tanya held senior roles directing global talent acquisition strategies at a major publicly-traded technology firm, advising on organizational design and succession planning for emerging executive functions. She is a recognized speaker and contributor to industry events, sharing data-driven insights on executive compensation, leadership development, and the measurable business impact of C-suite talent.

Connect with Tanya to discuss your executive search needs.